High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H. Jansson, Kathleen Kelly, Supreet Agarwal et al.|Scientific Reports|2018Cited by 33
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuitIlya S. Senatorov, Kathleen Kelly, Joel M. Bowman et al.|Cell Reports Medicine|2024Cited by 5
Abstract B018: A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancerKeith H. Jansson, Kathleen Kelly, John B. Tucker et al.|Cancer Research|2018Cited by 0